Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II QL1706 + nab-paclitaxel + lenvatinib for HER2-negative advanced gastric/GEJ adenocarcinoma (second-line)
ChiCTR2600117590Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706, paclitaxel and lenvatinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective response rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QL1706paclitaxellenvatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600117590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117590.